title: microRNA-340 Suppresses Tumorigenic Potential of Prostate Cancer Cells by Targeting High-Mobility Group Nucleosome-Binding Domain 5.
abstract: Aberrantly expressed microRNAs (miRs) are extensively involved in tumorigenesis. microRNA-340 (miR-340) has been reported as a tumor suppressor in various cancer types. However, whether miR-340 plays an important role in prostate cancer remains unknown. This study aims to investigate the expression pattern of miR-340 and its functional significance in prostate cancer. Results showed that miR-340 expression was frequently downregulated in human prostate cancer cell lines and cancer tissues. miR-340 overexpression suppressed proliferative and invasive properties of prostate cancer cells. This overexpression also promoted prostate cancer cell apoptosis. Conversely, miR-340 silencing showed an opposite effect. Intriguingly, on the basis of bioinformatics analysis and luciferase reporter assay, we found that miR-340 directly targeted the 3'-untranslated region of the high-mobility group nucleosome-binding domain 5 (HMGN5). Quantitative polymerase chain reaction and western blot analysis further verified the results and demonstrated that miR-340 regulated HMGN5 expression. Correlation analysis also showed that HMGN5 expression levels were significantly inversely correlated with the miR-340 expression in prostate cancer tissues. Furthermore, miR-340 overexpression significantly decreased the protein expression of cyclin B1, Bcl-2, and matrix metalloproteinase-9, which are critical regulators for maintaining tumorigenic potential of cancer cells. In addition, overexpression of HMGN5 significantly reversed the inhibitory effect of miR-340 on prostate cancer cell proliferation and invasion. In summary, this study suggests that miR-340 suppresses the tumorigenic potential of prostate cancer cells. Moreover, the decreased miR-340 expression may contribute to the development and progression of prostate cancer through a mechanism that involves HMGN5. Thus, miR340 and its target gene HMGN5 can serve as potentially useful therapeutic candidates for prostate cancer treatment.
authors.affiliation: 1 Department of Urology, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, China .|2 Department of Urology, Luoyang Central Hospital Affiliated to Zhengzhou University , Luoyang, China .
authors.forename: Pengtao
authors.initials: P
authors.lastname: Wei
authors.affiliation: 1 Department of Urology, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, China .
authors.forename: Baoping
authors.initials: B
authors.lastname: Qiao
authors.affiliation: 1 Department of Urology, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, China .
authors.forename: Qi
authors.initials: Q
authors.lastname: Li
authors.affiliation: 2 Department of Urology, Luoyang Central Hospital Affiliated to Zhengzhou University , Luoyang, China .
authors.forename: Xingtao
authors.initials: X
authors.lastname: Han
authors.affiliation: 2 Department of Urology, Luoyang Central Hospital Affiliated to Zhengzhou University , Luoyang, China .
authors.forename: Han
authors.initials: H
authors.lastname: Zhang
authors.affiliation: 2 Department of Urology, Luoyang Central Hospital Affiliated to Zhengzhou University , Luoyang, China .
authors.forename: Qingxiang
authors.initials: Q
authors.lastname: Huo
authors.affiliation: 2 Department of Urology, Luoyang Central Hospital Affiliated to Zhengzhou University , Luoyang, China .
authors.forename: Jiantao
authors.initials: J
authors.lastname: Sun
mesh_terms: D017209:Apoptosis / Q000235:genetics; D063646:Carcinogenesis / Q000235:genetics*; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation / Q000235:genetics; D015536:Down-Regulation / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor / Q000502:physiology; D024001:HMGN Proteins / Q000235:genetics*; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000502:physiology*; D009361:Neoplasm Invasiveness; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D015534:Trans-Activators / Q000235:genetics*; D014407:Tumor Cells, Cultured
chemical_list: D024001:HMGN Proteins; C429289:HMGN5 protein, human; C570046:MIRN340 microRNA, human; D035683:MicroRNAs; D015534:Trans-Activators